473730-94-8

Basic information

• Product Name: (3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone
• Synonyms: (3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone
• CAS NO: 473730-94-8
• Molecular Formula: C10H12N2O3
• Molecular Weight: 208.21388
• Mol File: 473730-94-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone(473730-94-8)
• EPA Substance Registry System: (3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone(473730-94-8)

Safety Data

• Hazardous Substances Data: 473730-94-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone is used as a potential pharmaceutical candidate for various applications due to its unique structure and ability to interact with biological systems. Its functional groups may allow it to target specific biological pathways or receptors, making it a promising compound for the development of new drugs.
Used in Medicinal Applications:
(3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone is used as a potential medicinal compound for the treatment of various diseases and conditions. Its unique structure and functional groups may enable it to modulate biological processes or target specific molecular pathways, offering new therapeutic options for patients.
Note: The specific applications and reasons for using (3-aMino-2-hydroxyphenyl)(3-hydroxyazetidin-1-yl)Methanone in the pharmaceutical and medicinal industries are not provided in the materials. The uses listed above are general and based on the potential of the compound's structure and functional groups. Further research is required to determine the exact applications and reasons for its use in these industries.

Relevant articles and documents

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.